PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta - Jakarta Delayed price. Currency in IDR
Add to watchlist
As of 11:50AM WIB. Market open.
| Previous close | 1,750.00 |
| Open | 1,715.00 |
| Bid | 1,740.00 x 0 |
| Ask | 1,745.00 x 0 |
| Day's range | 1,735.00 - 1,770.00 |
| 52-week range | 1,375.00 - 1,865.00 |
| Volume | |
| Avg. volume | 30,894,467 |
| Market cap | 80.694T |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 26.52 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 31.00 (1.77%) |
| Ex-dividend date | 29 May 2024 |
| 1y target est | N/A |
- Business Wire
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.